Dear colleagues,
This summer the Division of Pharmacoepidemiology & Pharmacotherapy at the Utrecht Institute for Pharmaceutical Sciences in Utrecht University, The Netherlands, will host two Summer Courses that may be of special interest to e-drug readers:
- a course on Pharmaceutical Policy Analysis, organised in collaboration with WHO (23-27 June 2008) and
- a course on Pharmacoepidemiology & Drug Safety (30 June - 4 July 2008).
A description of both courses can be found below. The fee of each of the courses is Euro 850. Both courses can be combined at a 'combination fee' of Euro 1,350. For more information about the application procedure, and all other courses in the Utrecht Summer School 2008, please visit www.utrechtsummerschool.nl/ , or contact Aukje Mantel-Teeuwisse ( A.K.Mantel@uu.nl ) or Olaf Klungel ( O.H.Klungel@uu.nl )
The deadline for registration is 31st May 2007.
Kind Regards,
Aukje Mantel-Teeuwisse, PhD
Utrecht University, Faculty of Science
Utrecht Institute for Pharmaceutical Sciences
Division of Pharmacoepidemiology & Pharmacotherapy
PO Box 80 082, 3508 TB Utrecht, The Netherlands
Tel: +31 30 253 6993
Fax: + 31 30 253 9166
E-mail: A.K.Mantel@uu.nl
1) Course "Pharmaceutical Policy Analysis" (23-27 June 2008)
Medicines are among the most regulated products in society. From the earliest pre-clinical stages onward, policy makers want to foster the development of safe, effective and affordable medicines for patients in need of pharmacotherapy. Priority Medicines and Orphan Drugs are examples of concepts that aim to energise new 'social contracts' between society and drug innovators.
When a drug reaches the market, it is the beginning of a process of complex interactions between patients, prescribers, pharmacists, insurers, pharmaceutical companies and governments. Furthermore, from a global perspective, the reality is that two billion people do not have access to essential medicines. The inequity in access to medicines is still a defining characteristic of the global pharmaceutical market place.
This course will cover these issues from a scientific, regulatory, public health and international policy perspective. As a collaborator on this course, the World Health Organization will provide faculty for several of the sessions.
COURSE LEADERS
Prof. Dr. Bert Leufkens (Utrecht University & Dutch Medicines Evaluation Board)
Dr. Richard Laing (World Health Organization), and
Dr. Aukje Mantel-Teeuwisse (Utrecht University)
TARGET GROUP
(Post)graduates and professionals within governments, NGOs, industry, universities with a basic knowledge of public health/medicine or pharmacy who have an interest in the policy aspects of pharmaceuticals.
AIM OF THE COURSE
The aim of the course is to give students insight into current developments in pharmaceutical policy making as well to give a better understanding of the methods available for analysing the effects of policy interventions.
COURSE FEE
Euro 850,- (includes course materials, lunches, course dinner, excludes housing)
(Euro 1,025,- Euro with student accommodation included)
2) Course "Pharmacoepidemiology and Drug Safety" (30 June - 4 July 2008)
With the prospect that innovative drug therapies will be introduced in the coming years, society demands new approaches and concepts for comparative risk/benefit evaluation. These evaluations are carried out once these therapies have been used widely in daily practice.
Assessment of safety and risk management of different drug therapies is done in the framework of observational epidemiological studies (proof of "safety", proof of "effectiveness"). This is the logical next step after randomized clinical trials, which are designed to provide evidence of a drugs "efficacy".
The course will cover key issues in pharmacoepidemiologic and drug safety research. Special topics include linking databases and molecular pharmacoepidemiology. All course teachers have extended expertise in the design and conduct of pharmacoepidemiologic studies.
COURSE LEADER
Dr. O.H. Klungel
LECTURERES
Prof. S. Suissa, Prof. H.G.M. Leufkens, Prof. A. de Boer, Prof. A.C.G. Egberts, Dr. O.H. Klungel, Dr. T. van Staa.
TARGET GROUP
Postgraduates, clinicians and professionals within governments, industry, universities with a basic knowledge of epidemiology and an interest in pharmacoepidemiology and risk/benefit evaluation of drug therapies.
AIM OF THE COURSE
In this course students will learn about the typical problems (e.g. confounding by indication, rare side effects) and approaches to deal with these problems in the practice of Pharmacoepidemiology.
COURSE FEE
Euro 850,- (includes course materials, lunches, course dinner, excludes housing)
(Euro 1,025,- Euro with student accommodation included)